IP Library Patent Application 15389291
Patent Application
App. No. 15/389,291

VIRAL INACTIVATION USING IMPROVED SOLVENT-DETERGENT METHOD

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/389,291
Abstract

The present specification discloses methods of inactivating a lipid-coat containing virus and proteins essentially free of a lipid-coat containing virus obtained from such methods.

Claims (26)

1 - 85 . (canceled)

86 . A method of inactivating a lipid-coat containing virus, the method comprising:

(a) admixing tri(n-butyl) phosphate, polyoxyethylene octyl phenyl, and polysorbate 80 sorbitan with a cell culture supernatant comprising recombinant Factor VIII having a first activity, thereby forming a mixture, wherein the admixing is conducted at a temperature from 2° C. to 6° C., and wherein the final concentration of tri(n-butyl) phosphate in the mixture is from about 0.1% (v/v) to about 5.0% (v/v), the final concentration of polyoxyethylene octyl phenyl in the mixture is from about 0.5% (v/v) to about 10.0% (v/v), and the final concentration of polysorbate 80 sorbitan in the mixture is from about 0.1% (v/v) to about 5.0% (v/v); and

(b) incubating the mixture for no more than about 120 minutes at a temperature of from 2° C. to 6° C., thereby forming an incubated mixture, essentially free of viable lipid-coat containing virus, and

wherein Factor VIII in the incubated mixture has a second activity of at least 25% of the first activity.

87 . The method of claim 86 , wherein the final concentration of tri(n-butyl) phosphate is from about 0.1% (v/v) to about 0.7%, the final concentration of polyoxyethylene octyl phenyl is from about 0.6% (v/v) to about 1.4% (v/v), and the final concentration of polysorbate 80 sorbitan is from about 0.1% (v/v) to about 0.7%

88 . The method of claim 86 , wherein the final concentration of tri(n-butyl) phosphate is from about 0.1% (v/v) to about 0.5%, the final concentration of polyoxyethylene octyl phenyl is from about 0.7% (v/v) to about 1.3% (v/v), and the final concentration of polysorbate 80 sorbitan is from about 0.1% (v/v) to about 0.5%

89 . The method of claim 86 , wherein the final concentration of tri(n-butyl) phosphate is from about 0.2% (v/v) to about 0.4%, the final concentration of polyoxyethylene octyl phenyl is from about 0.8% (v/v) to about 1.2% (v/v), and the final concentration of polysorbate 80 sorbitan is from about 0.2% (v/v) to about 0.4%.

90 . The method of claim 86 , wherein the final concentration of tri(n-butyl) phosphate is about 0.3% (v/v), the final concentration of polyoxyethylene octyl phenyl is about 1.0% (v/v), and the final concentration of polysorbate 80 sorbitan is about 0.3% (v/v).

91 . The method of claim 86 , wherein less than 1% of the Factor VIII in the incubated mixture is aggregated.

92 . The method of claim 86 , wherein Factor VIII in the incubated mixture has a second activity of at least 50% of the first activity.

93 . The method of claim 86 , wherein the mixture is incubated in step (b) for no more than about 60 minutes.

94 . The method of claim 86 , wherein the mixture is incubated in step (b) for no more than about 30 minutes.

95 . The method of claim 86 , wherein the mixture is incubated in step (b) for no more than about 10 minutes.

96 . The method of claim 86 , wherein both steps (a) and (b) are performed at a temperature of from 2° C. to 4° C.

97 . The method of claim 86 , wherein both steps (a) and (b) are performed at a temperature of about 4° C.

98 . The method of claim 86 , wherein the method is capable of reducing the viral infectivity of a herpesviridae virus in the cell culture supernatant by at least 4 log.

99 . The method of claim 86 , wherein the method is capable of reducing the viral infectivity of a flaviviridae virus in the cell culture supernatant by at least 4 log.

100 . The method of claim 86 , wherein the method is capable of reducing the viral infectivity of pseudorabies virus (PRV) in the fluid by at least 4 log.

101 . A composition comprising Factor VIII that is essentially free of a lipid-coat containing virus prepared according to the method of claim 86 .

102 . A method of inactivating a lipid-coat containing virus, the method comprising:

(a) admixing an alkylphosphate and at least two non-ionic surfactants with a fluid comprising a blood protein having a first activity, thereby forming a mixture; and

(b) incubating the mixture for no more than about 120 minutes, thereby forming an incubated mixture,

wherein the incubated mixture is essentially free of viable lipid-coat containing virus, and

wherein the blood protein in the incubated mixture has a second activity of at least 25% of the first activity.

103 . A composition comprising a blood factor that is essentially free of a lipid-coat containing virus prepared according to the method of claim 102 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055189/0238 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: FELGENHAUER, MARTIN; MISON, DOMINIQUE; MONTANDON, FREDERIC; FARCET, MARIA
To: BAXTER HEALTHCARE SA; BAXTER INTERNATIONAL INC.
Reel/Frame 044860/0386 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 045280/0263 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 045280/0619 →